Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer

Overview of attention for article published in OncoTargets and therapy, September 2015

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 22 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 10 publications that cite this research output.

10

The most recent citing publications are shown below. View all 10 publications that cite this research output on Dimensions.

Rare Mucinous Adenocarcinoma of the Appendix Undergoing Multiple Recurrent Surgical Interventions

Article in Cureus (January 2023)

Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study

Article in BMC Cancer (January 2021)

Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion

Article in Clinical Colorectal Cancer (April 2020)